Dishman is expecting growth of about 20% for its CRAMS segment in the next year according to cfo V V S Murthy. He put this down to easing of inventory rationalisation by big pharma and increasing outsourcing to India.
DNA India
Wednesday 6 January 2010
Dishman seeks 20% growth in CRAMS
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment